GW-501516 vs Testosterone for performance
Short answer: For performance, users rate them about the same: 93% report improvement with GW-501516 (75 reports) and 97% with Testosterone (149 reports).
GW-501516 has 0 meta-analyses and 0 randomized trials on PubMed; Testosterone has 75 and 125.
Based on 317 reports about GW-501516 and 822 about Testosterone. Not medical advice.
| GW-501516 Substance | Testosterone Medication | |
|---|---|---|
| User score | 48 | 54 |
| Verdict | Mostly positive | Mostly positive |
| Positive of reports that state an outcome | 65% | 77% |
| Reports | 317 | 822 |
| Research | DResearch: None | AResearch: Strong |
| Meta-analyses / RCTs | 0 / 0 | 75 / 125 |
| Mainly used for | ||
| Weight loss % reporting improvement | 85% (52) | 93% (45) |
| Appetite % reporting improvement | 50% (4) | — |
| Focus % reporting improvement | — | 82% (28) |
| Energy % reporting improvement | 95% (19) | 92% (76) |
| Sleep % reporting improvement | 0% (2) | 79% (19) |
| Anxiety % reporting improvement | — | 80% (25) |
| Mood % reporting improvement | 100% (2) | 88% (104) |
| Memory % reporting improvement | — | 100% (2) |
| Performance % reporting improvement | 93% (75) | 97% (149) |
| Recovery % reporting improvement | 100% (3) | 91% (23) |
| Pain & inflammation % reporting improvement | — | 67% (6) |
| Libido % reporting improvement | — | 93% (70) |
| Hormones % reporting improvement | — | 90% (91) |
| Heart & lipids % reporting improvement | 86% (22) | 62% (8) |
| Skin & hair % reporting improvement | — | 40% (5) |
| Longevity % reporting improvement | 50% (2) | 50% (2) |
| Common side effects | cancer risk, acne, fatigue, brain fog | suppression, hair loss, acne, water retention |
| Typical dose reported | 20 mg / daily | 200 mg / weekly |
GW-501516Full GW-501516 profile →
What a user said
“For weight loss Cardarine is good. It tells your body to use fat as energy... my body fat has dropped abit but not loads but it's been 2 weeks.”
TestosteroneFull Testosterone profile →
Latest review conclusion
The guidelines also provide recommendations regarding identification of patients, dosing, monitoring, and follow-up. This Practice Pearl will discuss evidence-based testosterone therapy for management of HSDD in postmenopausal women.
Menopause, 2023 ↗What a user said
“Feel the best I've ever felt in my life. TRT and peptides have been game changers for me!”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate